Analyst Patrick Wood of Morgan Stanley maintained a Sell rating on Integra Lifesciences (IART – Research Report), retaining the price target of $20.00.
Patrick Wood has given his Sell rating due to a combination of factors affecting Integra Lifesciences. The company’s recent quarterly performance showed mixed results, with organic growth aligning with expectations but earnings per share only surpassing projections due to non-operational factors like tax benefits. Furthermore, the guidance for 2025, particularly for the first quarter, fell short of market expectations, indicating a potential decline in organic growth.
Additionally, the abrupt deceleration from the previous quarter’s growth to the projected decline raises concerns about the company’s future performance. The transition under new leadership and the impact of the Compliance Master Plan add layers of uncertainty. These elements, combined with the current market positioning and short interest, contribute to the cautious outlook and the decision to rate the stock as a Sell.
According to TipRanks, Wood is a 3-star analyst with an average return of 4.9% and a 57.14% success rate. Wood covers the Healthcare sector, focusing on stocks such as Boston Scientific, Intuitive Surgical, and Insulet.
In another report released yesterday, Bank of America Securities also reiterated a Sell rating on the stock with a $21.00 price target.